Index to volume 58

Author index

A

Abernethy DR, Laurie N, Andrawis NS. Local angiotensin-converting enzyme inhibition blunts endothelin-1–induced increase in forearm vascular resistance. 1995;58:328-34
Acott PD (*see* McLellan et al). 1995;58:322-7
Affrime MB (*see* Brannan et al). 1995;58:269-78
— (*see* Hulsman et al). 1995;58:383-9
— (*see* Reidenberg et al). 1995;58:279-87
— (*see* Saano et al). 1995;58:523-31
Agrawal S (*see* Zhang et al). 1995;58:44-53
Albrecht R (*see* Hughes et al). 1995;58:434-43
Amin G (*see* Zhang et al). 1995;58:44-53
Andrawis NS (*see* Abernethy et al). 1995;58:328-34
Antal EJ (*see* Hughes et al). 1995;58:434-43
Antoni G (*see* Hartvig et al). 1995;58:165-73
Anttila M (*see* Huupponen et al). 1995;58:506-11
Asthana S, Greig NH, Hegedus L, Holloway HH, Raffaele KC, Schapiro MB, Soncrant TT. Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease. 1995;58:299-309

B

Bagatin J (*see* Rumboldt et al). 1995;58:237-8 (Letter)
Bakke OM, Manocchia M, de Abajo F, Kaitin KI, Lasagna L. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. 1995;58:108-17
Banfield CR (*see* Hulsman et al). 1995;58:383-9
— (*see* Reidenberg et al). 1995;58:279-87
— (*see* Saano et al). 1995;58:523-31
Barbey JT (*see* Yasuda et al). 1995;58:210-20
Barbhaiya RH, Shukla UA, Natarajan CS, Behr DA, Greene DS, Sainati SM. Single- and multiple-dose pharmacokinetics of nefazodone in patients with hepatic cirrhosis. 1995;58:390-8
Barchowsky A (*see* Cutler et al). 1995;58:54-61
Barre J (*see* Plaud et al). 1995;58:185-91
Bedarida G, Bushell E, Blaschke TF, Hoffman BB. H_1- and H_2-histamine receptor–mediated vasodilation varies with aging in humans. 1995;58:73-80
Behr DA (*see* Barbhaiya et al). 1995;58:390-8
Benet LZ (*see* Gomez et al). 1995;58:15-9
— (*see* Wu et al). 1995;58:492-7
Benowitz NL, Jacob P III, Mayan H, Denaro C. Sympathomimetic effects of paraxanthine and caffeine in humans. 1995;58:684-91
Berlin I. Buspirone miosis. 1995;58:600-1 (Letter)
—, Saïd S, Spreux-Varoquaux O, Launay JM, Olivares R, Millet V, Lecrubier Y, Puech AJ. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. 1995;58:444-52
Bernabei R (*see* Pahor et al). 1995;58:470-81
Bienz-Tadmor B (*see* Brown et al). 1995;58:243-56 (Commentary)
Bjornsson TD (*see* Lo et al). 1995;58:641-9
Blaschke TF (*see* Bedarida et al). 1995;58:73-80
Blöchl-Daum B, Pehamberger H, Kurz C, Kyrle PA, Wagner O, Müller M, Monitzer B, Eichler HG. Effects of cisplatin on urinary thromboxane B_2 excretion. 1995;58:418-24
Bowsher RR (*see* Howey et al). 1995;58:459-69
Brannan MD, Reidenberg P, Radwanski E, Shneyer L, Lin CC, Cayen MN, Affrime MB. Loratadine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations. 1995;58:269-78
Brass EP (*see* Cutler et al). 1995;58:54-61
Braun RE (*see* Margarone et al). 1995;58:453-8
Brown A (*see* Welch et al). 1995;58:132-42
Brown JS, Bienz-Tadmor B, Lasagna L. Availability of anticancer drugs in the United States, Europe, and Japan from 1960 through 1991. 1995;58:243-56 (Commentary)
Brown M (*see* Stein et al). 1995;58:425-33
Brunelle RL (*see* Howey et al). 1995;58:459-69
Bushell E (*see* Bedarida et al). 1995;58:73-80

C

Caraco Y, Tateishi T, Wood AJJ. Interethnic difference in omeprazole's inhibition of diazepam metabolism. 1995;58:62-72
— (*see* Zylber-Katz et al). 1995;58:198-209
Carbonin P (*see* Pahor et al). 1995;58:470-81
Carleborg L (*see* Spigset et al). 1995;58:399-403
Carosella L (*see* Pahor et al). 1995;58:470-81
Cayen MN (*see* Brannan et al). 1995;58:269-78
Cecchi E (*see* Pahor et al). 1995;58:470-81
Chandrasekar PH (*see* Ducharme et al). 1995;58:617-24
Chiang ST (*see* van Griensven et al). 1995;58:631-40
Chiba K (*see* Ishizaki et al). 1995;58:155-64
— (*see* Yasuda et al). 1995;58:143-54
Choma N (*see* Mould et al). 1995;58:35-43
Cipollone F, Ganci A, Panara MR, Greco A, Cuccurullo F, Patrono C, Patrignani P. Effects of nabumetone on prostanoid biosynthesis in humans. 1995;58:335-41
Clipp EC, Moore MJ. Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease. 1995;58:228-36
Cocchi A (*see* Pahor et al). 1995;58:470-81
Cohen AF (*see* van Griensven et al). 1995;58:631-40
Colangelo PM (*see* Harris et al). 1995;58:310-5
Colucci RD (*see* Hulsman et al). 1995;58:383-9
— (*see* Reidenberg et al). 1995;58:279-87
— (*see* Saano et al). 1995;58:523-31
Conrad KA. Clinical pharmacology and drug safety: lessons from hirudin. 1995;58:123-6 (Commentary)
Crews T (*see* Mould et al). 1995;58:35-43
Crocker JFS (*see* McLellan et al). 1995;58:322-7
Cuccurullo F (*see* Cipollone et al). 1995;58:335-41
Cutler NR, Seifert RD, Schleman MM, Sramek JJ, Szylleyko OJ, Howard DR, Barchowsky A, Wardle TS, Brass EP. Acetylcholinesterase inhibition by zifrosilone: pharmacokinetics and pharmacodynamics. 1995;58:54-61

D

D'Agostino RB, Weintraub M. Meta-analysis: a method for synthesizing research. 1995;58:605-16 (Commentary)
Dahl R (*see* Welch et al). 1995;58:132-42
Dahlqvist R (*see* Spigset et al). 1995;58:399-403
Dannenberg AJ (*see* Kashfi et al). 1995;58:625-30
Dayer P (*see* Transon et al). 1995;58:412-7
de Abajo F (*see* Bakke et al). 1995;58:108-17
Debaene B (*see* Plaud et al). 1995;58:185-91
DeFeo TM (*see* Mould et al). 1995;58:35-43
de Groot R (*see* van den Anker et al). 1995;58:650-9
Delaney C (*see* Kostis et al). 1995;58:660-5
de Morais SMF, Goldstein JA, Xie HG, Huang SL, Lu YQ, Xia H, Xiao ZS, Ile N, Zhou HH. Genetic analysis of the *S*-mephenytoin polymorphism in a Chinese population. 1995;58:404-11
Denaro C (*see* Benowitz et al). 1995;58:684-91
Desai N (*see* Oo et al). 1995;58:548-55

Diasio RB (*see* Lu et al). 1995;58:512-22
— (*see* Zhang et al). 1995;58:44-53
DiMasi JA. Success rates for new drugs entering clinical testing in the United States. 1995;58:1-14 (Commentary)
Doenicke A, Moss J, Lorenz W, Hoernecke R. Intravenous morphine and nalbuphine increase histamine and catecholamine release without accompanying hemodynamic changes. 1995;58:81-9
Dohi Y (*see* Sato et al). 1995;58:583-7
Domino EF (*see* Kishimoto et al). 1995;58:666-74
Downing-Shelton J (*see* Howey et al). 1995;58:459-69
Dreisbach AW, Ferencz N, Hopkins NE, Fuentes MG, Rege AB, George WJ, Lertora JJL. Urinary excretion of 6-hydroxychlorzoxazone as an index of CYP2E1 activity. 1995;58:498-505
Drobitch RK (*see* McLellan et al). 1995;58:322-7
Ducharme MP, Slaughter RL, Warbasse LH, Chandrasekar PH, Van de Velde V, Mannens G, Edwards DJ. Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. 1995;58:617-24

E

Edwards DJ (*see* Ducharme et al). 1995;58:617-24
Egan TE (*see* Fiset et al). 1995;58:567-82
Eichler HG (*see* Blöchl-Daum et al). 1995;58:418-24
Elkins L (*see* Stoltz et al). 1995;58:342-53
Eller M (*see* Harris et al). 1995;58:310-5

F

Fanciullacci M, Geppetti P. Buspirone miosis. 1995;58:601 (Letter reply)
Fattinger KE, Verotta D. Estimating bioavailability when clearance changes in time: the effect of model misspecification. 1995;58:595-9 (Letter)
Ferencz N (*see* Dreisbach et al). 1995;58:498-505
Fiset P, Lemmens HLM, Egan TE, Shafer SL, Stanski DR. Pharmacodynamic modeling of the electroencephalographic effects of flumazenil in healthy volunteers sedated with midazolam. 1995;58:567-82
Flockhart DA (*see* Hadidi et al). 1995;58:542-7
Fong J, Johnston S, Valentino T, Notterman D. Length/serum creatinine ratio does not predict measured creatinine clearance in critically ill children. 1995;58:192-7
Francom SF (*see* Hughes et al). 1995;58:434-43
Freeman A (*see* Gertz et al). 1995;58:288-98
Fromm MF, Hofmann U, Griese EU, Mikus G. Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans. 1995;58:374-82
Fuentes MG (*see* Dreisbach et al). 1995;58:498-505
Fuhr U, Kummert AL. The fate of naringin in humans: A key to grapefruit juice–drug interactions? 1995;58:365-73
Fumagalli S (*see* Pahor et al). 1995;58:470-81
Funck-Brentano C (*see* Partovian et al). 1995;58:257-63
Furtek CI (*see* Lo et al). 1995;58:641-9

G

Gambassi G (*see* Pahor et al). 1995;58:470-81
Ganci A (*see* Cipollone et al). 1995;58:335-41
Garbutt-Sculli L (*see* Jamieson et al). 1995;58:594
Garland WT (*see* Kostis et al). 1995;58:660-5
George WJ (*see* Dreisbach et al). 1995;58:498-505
Geppetti P (*see* Fanciullacci and Geppetti). 1995;58:601 (Letter reply)
Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Quan H, Lasseter KC, Mucklow JC, Porras AG. Studies of the oral bioavailability of alendronate. 1995;58:288-98
Glue P (*see* Hulsman et al). 1995;58:383-9
— (*see* Reidenberg et al). 1995;58:279-87
— (*see* Saano et al). 1995;58:523-31
Golczynska A, Lenders JWM, Goldstein DS. Glucocorticoid-induced sympathoinhibition in humans. 1995;58:90-8
Goldberg MR (*see* Lo et al). 1995;58:641-9
Goldstein DS (*see* Golczynska et al). 1995;58:90-8
Goldstein JA (*see* de Morais et al). 1995;58:404-11
Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. 1995;58:15-9
— (*see* Wu et al). 1995;58:492-7
Gordin A (*see* Illi et al). 1995;58:221-7
Granit L (*see* Zylber-Katz et al). 1995;58:198-209
Greco A (*see* Cipollone et al). 1995;58:335-41
Greene DS (*see* Barbhaiya et al). 1995;58:390-8
Greig NH (*see* Asthana et al). 1995;58:299-309
Griese EU (*see* Fromm et al). 1995;58:374-82
Gruppo Italiano di Farmacovigilanza nell'Anziano (*see* Pahor et al). 1995;58:470-81
Guillaume M (*see* Reidenberg et al). 1995;58:279-87
Gupta SK (*see* Wu et al). 1995;58:492-7
Gustafsson LL (*see* Hartvig et al). 1995;58:165-73

H

Ha HR (*see* Kupferschmidt et al). 1995;58:20-8
Hadidi HF, Irshaid YM, Woosley RL, Idle JR, Flockhart DA. *S*-Mephenytoin hydroxylation phenotypes in a Jordanian population. 1995;58:542-7
Haefeli WE (*see* Peduzzi et al). 1995;58:675-83
Hall RE (*see* Margarone et al). 1995;58:453-8
Hansen SR (*see* Straka et al). 1995;58:29-34
Haring P (*see* Saano et al). 1995;58:523-31
Harris S, Hilligoss DM, Colangelo PM, Eller M, Okerholm R. Azithromycin and terfenadine: lack of drug interaction. 1995;58:310-5
Hartvig P, Valtysson J, Lindner KJ, Kristensen J, Karlsten R, Gustafsson LL, Persson J, Svensson JO, Øye I, Antoni G, Westerberg G, Långström B. Central nervous system effects of subdissociative doses of *(S)*-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers. 1995;58:165-73
Hayashi M (*see* Ishizaki et al). 1995;58:155-64
He H (*see* Stein et al). 1995;58:425-33
Hebert MF (*see* Gomez et al). 1995;58:15-9
— (*see* Wu et al). 1995;58:492-7
Hedenmalm K (*see* Spigset et al). 1995;58:399-403
Hegedus L (*see* Asthana et al). 1995;58:299-309
Hilligoss DM (*see* Harris et al). 1995;58:310-5
Hoernecke R (*see* Doenicke et al). 1995;58:81-9
Hoffman BB (*see* Bedarida et al). 1995;58:73-80
Hofmann U (*see* Fromm et al). 1995;58:374-82
Holland SD (*see* Gertz et al). 1995;58:288-98
Holloway HH (*see* Asthana et al). 1995;58:299-309
Hop WCJ (*see* van den Anker et al). 1995;58:650-9
Hopkins NE (*see* Dreisbach et al). 1995;58:498-505
Horai Y (*see* Ishizaki et al). 1995;58:155-64
— (*see* Yasuda et al). 1995;58:143-54
Howard DR (*see* Cutler et al). 1995;58:54-61
Howey DC, Bowsher RR, Brunelle RL, Rowe HM, Santa PF, Downing-Shelton J, Woodworth JR. [Lys(B28), Pro(B29)]–human insulin: effect of injection time on postprandial glycemia. 1995;58:459-69
Huang Jd (*see* Lai et al). 1995;58:264-8
Huang SL (*see* de Morais et al). 1995;58:404-11
Hughes GS Jr, Yancey EP, Albrecht R, Locker PK, Francom SF, Orringer EP, Antal EJ, Jacobs EE Jr. Hemoglobin-based oxygen carrier preserves submaximal exercise capacity in humans. 1995;58:434-43

Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ. Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. 1995;58:127-31
Hulsman JARJ, Rentmeester TW, Banfield CR, Reidenberg P, Colucci RD, Meehan JW, Radwanski E, Mojaverian P, Lin CC, Nezamis J, Affrime MB, Glue P. Effects of felbamate on the pharmacokinetics of the monohydroxy and dihydroxy metabolites of oxcarbazepine. 1995;58:383-9
Huupponen R, Karhuvaara S, Anttila M, Vuorilehto L, Scheinin H. Buccal delivery of an α_2-adrenergic receptor antagonist, atipamezole, in humans. 1995;58:506-11

I

Idle JR (*see* Hadidi et al). 1995;58:542-7
Ile N (*see* de Morais et al). 1995;58:404-11
Illi A, Sundberg S, Ojala-Karlsson P, Korhonen P, Scheinin M, Gordin A. The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine. 1995;58:221-7
Irshaid YM (*see* Hadidi et al). 1995;58:542-7
Ishizaki T, Chiba K, Manabe K, Koyama E, Hayashi M, Yasuda S, Horai Y, Tomono Y, Yamato C, Toyoki T. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of *S*-mephenytoin 4′-hydroxylation. 1995;58:155-64
— (*see* Yasuda et al). 1995;58:143-54

J

Jacob P III (*see* Benowitz et al). 1995;58:684-91
Jacobs EE Jr (*see* Hughes et al). 1995;58:434-43
Jacqz-Aigrain E (*see* Partovian et al). 1995;58:257-63
Jaehde U, Sörgel F, Reiter A, Sigl G, Naber KG, Schunack W. Effect of probenecid on the distribution and elimination of ciprofloxacin in humans. 1995;58:532-41
Jaillon P (*see* Partovian et al). 1995;58:257-63
Jamieson MJ, Garbutt-Sculli L, Shepherd AMM. Miscompliance by proxy. 1995;58:594
Jensen PK (*see* Saano et al). 1995;58:523-31
Jiang Z (*see* Zhang et al). 1995;58:44-53
Johnston S (*see* Fong et al). 1995;58:192-7
Jorch U (*see* Spahr-Schopfer et al). 1995;58:316-21
Jusko WJ (*see* van Griensven et al). 1995;58:631-40

K

Kadoya C (*see* Kishimoto et al). 1995;58:666-74
Kaitin KI (*see* Bakke et al). 1995;58:108-17
Kalhorn TF (*see* Mitra et al). 1995;58:556-66
Karhuvaara S (*see* Huupponen et al). 1995;58:506-11
Karim A, Piergies A. Verapamil stereoisomerism: enantiomeric ratios in plasma dependent on peak concentrations, oral input rate, or both. 1995;58:174-84
Karlsson M (*see* Sheiner and Karlsson). 1995;58:599-600 (Letter reply)
Karlsten R (*see* Hartvig et al). 1995;58:165-73
Kashfi K, McDougall CJ, Dannenberg AJ. Comparative effects of omeprazole on xenobiotic metabolizing enzymes in the rat and human. 1995;58:625-30
Keundjian A (*see* Partovian et al). 1995;58:257-63
Kharasch ED (*see* Mitra et al). 1995;58:556-66
Kishimoto T, Kadoya C, Sneyd R, Samra SK, Domino EF. Topographic electroencephalogram of propofol-induced conscious sedation. 1995;58:666-74
Kline WF (*see* Gertz et al). 1995;58:288-98
Kobayashi K (*see* Yasuda et al). 1995;58:143-54
Kojima M (*see* Sato et al). 1995;58:583-7
Korhonen P (*see* Illi et al). 1995;58:221-7
Kostis JB, Garland WT, Delaney C, Norton J, Liao Wc. Fosinopril: pharmacokinetics and pharmacodynamics in congestive heart failure. 1995;58:660-5
Koyama E (*see* Ishizaki et al). 1995;58:155-64
Krähenbühl S (*see* Kupferschmidt et al). 1995;58:20-8
Kristensen J (*see* Hartvig et al). 1995;58:165-73
Kroon R (*see* van Griensven et al). 1995;58:631-40
Kuhn RJ (*see* Oo et al). 1995;58:548-55
Kummert AL (*see* Fuhr and Kummert). 1995;58:365-73
Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krähenbühl S. Interaction between grapefruit juice and midazolam in humans. 1995;58:20-8
Kurz C (*see* Blöchl-Daum et al). 1995;58:418-24
Kyrle PA (*see* Blöchl-Daum et al). 1995;58:418-24

L

Lai MD (*see* Lai et al). 1995;58:264-8
Lai ML, Wang SL, Lai MD, Lin ET, Tse M, Huang Jd. Propranolol disposition in Chinese subjects of different *CYP2D6* genotypes. 1995;58:264-8
Lanctôt KL, Naranjo CA. Comparison of the Bayesian approach and a simple algorithm for assessment of adverse drug events. 1995;58:692-8
Långström B (*see* Hartvig et al). 1995;58:165-73
Lasagna L (*see* Bakke et al). 1995;58:108-17
— (*see* Brown et al). 1995;58:243-56 (Commentary)
Lasseter KC (*see* Gertz et al). 1995;58:288-98
Launay JM (*see* Berlin et al). 1995;58:444-52
Laurie N (*see* Abernethy et al). 1995;58:328-34
Lecrubier Y (*see* Berlin et al). 1995;58:444-52
Leemann T (*see* Transon et al). 1995;58:412-7
Lemkes HHPJ (*see* van Griensven et al). 1995;58:631-40
Lemmens HLM (*see* Fiset et al). 1995;58:567-82
Lenders JWM (*see* Golczynska et al). 1995;58:90-8
Lerman J (*see* Spahr-Schopfer et al). 1995;58:316-21
Lertora JJL (*see* Dreisbach et al). 1995;58:498-505
Levy M (*see* Zylber-Katz et al). 1995;58:198-209
Liao Wc (*see* Kostis et al). 1995;58:660-5
Liebow C (*see* Margarone et al). 1995;58:453-8
Likhari P (*see* Yasuda et al). 1995;58:210-20
Limjuco R (*see* Mould et al). 1995;58:35-43
Lin CC (*see* Brannan et al). 1995;58:269-78
— (*see* Hulsman et al). 1995;58:383-9
— (*see* Reidenberg et al). 1995;58:279-87
— (*see* Saano et al). 1995;58:523-31
Lin ET (*see* Lai et al). 1995;58:264-8
Linder L (*see* Peduzzi et al). 1995;58:675-83
Lindner KJ (*see* Hartvig et al). 1995;58:165-73
Liu T (*see* Zhang et al). 1995;58:44-53
Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD. Pharmacokinetics of losartan, an angiotensin II receptor antagonist and its active metabolite EXP3174 in humans. 1995;58:641-9
Locker PK (*see* Hughes et al). 1995;58:434-43
Lorenz W (*see* Doenicke et al). 1995;58:81-9
Lu H (*see* Lo et al). 1995;58:641-9
Lu YQ (*see* de Morais et al). 1995;58:404-11
Lu Z, Zhang R, Diasio RB. Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy. 1995;58:512-22
— (*see* Zhang et al). 1995;58:44-53
Luo X (*see* Sonnichsen et al). 1995;58:99-107

M

Manabe K (*see* Ishizaki et al). 1995;58:155-64
— (*see* Yasuda et al). 1995;58:143-54
Mannens G (*see* Ducharme et al). 1995;58:617-24

Manocchia M (*see* Bakke et al). 1995;58:108-17
Manto A (*see* Pahor et al). 1995;58:470-81
Marchionni N (*see* Pahor et al). 1995;58:470-81
Margarone JE, Liebow C, Hall RE, Braun RE, Weiner M. A comparison of crossover versus parallel-group design in the evaluation of analgesic efficacy after molar extraction. 1995;58:453-8
Martin RR (*see* Zhang et al). 1995;58:44-53
Mathew P (*see* Sonnichsen et al). 1995;58:99-107
Matuszewski BK (*see* Gertz et al). 1995;58:288-98
Mayan H (*see* Benowitz et al). 1995;58:684-91
McCrea JB (*see* Lo et al). 1995;58:641-9
McDougall CJ (*see* Kashfi et al). 1995;58:625-30
McLellan DH (*see* McLellan et al). 1995;58:322-7
McLellan RA, Drobitch RK, McLellan DH, Acott PD, Crocker JFS, Renton KW. Norfloxacin interferes with cyclosporine disposition in pediatric patients undergoing renal transplantation. 1995;58:322-7
McNamara PJ (*see* Oo et al). 1995;58:548-55
Meehan JW (*see* Hulsman et al). 1995;58:383-9
— (*see* Reidenberg et al). 1995;58:279-87
— (*see* Saano et al). 1995;58:523-31
Meier PJ (*see* Kupferschmidt et al). 1995;58:20-8
Meistelman C (*see* Plaud et al). 1995;58:185-91
Mikus G (*see* Fromm et al). 1995;58:374-82
Milla G (*see* Mould et al). 1995;58:35-43
Millet V (*see* Berlin et al). 1995;58:444-52
Mitra AK, Thummel KE, Kalhorn TF, Kharasch ED, Unadkat JD, Slattery JT. Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. 1995;58:556-66
Mojaverian P (*see* Hulsman et al). 1995;58:383-9
— (*see* Reidenberg et al). 1995;58:279-87
Monitzer B (*see* Blöchl-Daum et al). 1995;58:418-24
Moore MJ (*see* Clipp and Moore). 1995;58:228-36
Moss J (*see* Doenicke et al). 1995;58:81-9
Mould DR, DeFeo TM, Reele S, Milla G, Limjuco R, Crews T, Choma N, Patel IH. Simultaneous modeling of the pharmacokinetics and pharmacodynamics of midazolam and diazepam. 1995;58:35-43
Mucklow JC (*see* Gertz et al). 1995;58:288-98
Mugelli A (*see* Pahor et al). 1995;58:470-81
Müller M (*see* Blöchl-Daum et al). 1995;58:418-24
Mungall D (*see* White et al). 1995;58:588-93

N

Naber KG (*see* Jaehde et al). 1995;58:532-41
Nakai H (*see* Yasuda et al). 1995;58:143-54
Naranjo CA (*see* Lanctôt and Naranjo). 1995;58:692-8
Natarajan CS (*see* Barbhaiya et al). 1995;58:390-8
Neijens HJ (*see* van den Anker et al). 1995;58:650-9
Nelson R (*see* Stein et al). 1995;58:425-33
Neuvonen PJ (*see* Hukkinen et al). 1995;58:127-31
Nezamis J (*see* Hulsman et al). 1995;58:383-9
— (*see* Reidenberg et al). 1995;58:279-87
Nomeir A (*see* Saano et al). 1995;58:523-31
Norton J (*see* Kostis et al). 1995;58:660-5
Notterman D (*see* Fong et al). 1995;58:192-7

O

Ojala-Karlsson P (*see* Illi et al). 1995;58:221-7
Okerholm R (*see* Harris et al). 1995;58:310-5
Olivares R (*see* Berlin et al). 1995;58:444-52
Olkkola KT (*see* Hukkinen et al). 1995;58:127-31
Oo CY, Kuhn RJ, Desai N, McNamara PJ. Active transport of cimetidine into human milk. 1995;58:548-55
Orisakwe OE (*see* Ufearo and Orisakwe). 1995;58:354-9
Orringer EP (*see* Hughes et al). 1995;58:434-43
Øye I (*see* Hartvig et al). 1995;58:165-73

P

Pahor M, Cecchi E, Fumagalli S, Manto A, Pedone C, Carosella L, Cocchi A, Bernabei R, Gambassi G, Marchionni N, Mugelli A, Carbonin P, Gruppo Italiano di Farmacovigilanza nell'Anziano. Association of serum creatinine and age with headache caused by nitrates. 1995;58:470-81
Palmer J (*see* Spahr-Schopfer et al). 1995;58:316-21
Panara MR (*see* Cipollone et al). 1995;58:335-41
Partovian C, Jacqz-Aigrain E, Keundjian A, Jaillon P, Funck-Brentano C. Comparison of chloroguanide and mephenytoin for the in vivo assessment of genetically determined CYP2C19 activity in humans. 1995;58:257-63
Patel IH (*see* Mould et al). 1995;58:35-43
— (*see* Zhi et al). 1995;58:487-91 (Commentary)
Patrignani P (*see* Cipollone et al). 1995;58:335-41
Patrono C (*see* Cipollone et al). 1995;58:335-41
Pedone C (*see* Pahor et al). 1995;58:470-81
Peduzzi P, Simper D, Linder L, Strobel WM, Haefeli WE. Neuropeptide Y in human hand veins: pharmacologic characterization and interaction with cyclic guanosine monophosphate–dependent venodilators in vivo. 1995;58:675-83
Pehamberger H (*see* Blöchl-Daum et al). 1995;58:418-24
Persson J (*see* Hartvig et al). 1995;58:165-73
Piergies A (*see* Karim and Piergies). 1995;58:174-84
Plaud B, Proost JH, Wierda MKH, Barre J, Debaene B, Meistelman C. Pharmacokinetics and pharmacodynamics of rocuronium at the vocal cords and the adductor pollicis in humans. 1995;58:185-91
Porras AG (*see* Gertz et al). 1995;58:288-98
Proost JH (*see* Plaud et al). 1995;58:185-91
Puech AJ (*see* Berlin et al). 1995;58:444-52

Q

Quan H (*see* Gertz et al). 1995;58:288-98

R

Radwanski E (*see* Brannan et al). 1995;58:269-78
— (*see* Hulsman et al). 1995;58:383-9
— (*see* Reidenberg et al). 1995;58:279-87
— (*see* Saano et al). 1995;58:523-31
Raffaele KC (*see* Asthana et al). 1995;58:299-309
Rakhit A (*see* Zhi et al). 1995;58:487-91 (Commentary)
Ravitch J (*see* Welch et al). 1995;58:132-42
Reele S (*see* Mould et al). 1995;58:35-43
Rege AB (*see* Dreisbach et al). 1995;58:498-505
Reidenberg P, Glue P, Banfield CR, Colucci RD, Meehan JW, Radwanski E, Mojaverian P, Lin CC, Nezamis J, Guillaume M, Affrime MB. Effects of felbamate on the pharmacokinetics of phenobarbital. 1995;58:279-87
— (*see* Brannan et al). 1995;58:269-78
— (*see* Hulsman et al). 1995;58:383-9
— (*see* Saano et al). 1995;58:523-31
Reiter A (*see* Jaehde et al). 1995;58:532-41
Relling MV (*see* Sonnichsen et al). 1995;58:99-107
Rentmeester TW (*see* Hulsman et al). 1995;58:383-9
Renton KW (*see* McLellan et al). 1995;58:322-7
Reynolds D (*see* Stoltz et al). 1995;58:342-53
Ribeiro RC (*see* Sonnichsen et al). 1995;58:99-107
Romano P (*see* White et al). 1995;58:588-93
Rowe HM (*see* Howey et al). 1995;58:459-69
Rowland M (*see* Wu et al). 1995;58:492-7
Rumboldt Z, Bagatin J, Sardelić S. The role of oral dihydroergotamine in the management of vascular disorders. 1995;58:237-8 (Letter)

S

Saag MS (*see* Zhang et al). 1995;58:44-53

Saano V, Glue P, Banfield C, Reidenberg P, Colucci RD, Meehan J, Haring P, Radwanski E, Nomeir A, Lin CC, Jensen PK, Affrime MB. Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive. 1995;58:523-31
Saïd S (*see* Berlin et al). 1995;58:444-52
Sainati SM (*see* Barbhaiya et al). 1995;58:390-8
Salazar D (*see* Stoltz et al). 1995;58:342-53
Samra SK (*see* Kishimoto et al). 1995;58:666-74
Santa PF (*see* Howey et al). 1995;58:459-69
Sardelić S (*see* Rumboldt et al). 1995;58:237-8 (Letter)
Sato K, Sawada M, Kojima M, Dohi Y. Biphasic pressor responses to norepinephrine in humans. 1995;58:583-7
Sauer PJJ (*see* van den Anker et al). 1995;58:650-9
Sawada M (*see* Sato et al). 1995;58:583-7
Schapiro MB (*see* Asthana et al). 1995;58:299-309
Schechter PJ (*see* Zhang et al). 1995;58:44-53
Scheinin H (*see* Huupponen et al). 1995;58:506-11
Scheinin M (*see* Illi et al). 1995;58:221-7
Schleman MM (*see* Cutler et al). 1995;58:54-61
Schoemaker RC (*see* van den Anker et al). 1995;58:650-9
Schunack W (*see* Jaehde et al). 1995;58:532-41
Seay RE, Brundage RC, Jensen PD, Schilling CG, Edgren BE. Population pharmacokinetics of vancomycin in neonates (1994;56:169-75). 1995;58:142 (Correction)
Seifert RD (*see* Cutler et al). 1995;58:54-61
Shafer SL (*see* Fiset et al). 1995;58:567-82
Shahinian H (*see* Zhang et al). 1995;58:44-53
Sheiner LB, Karlsson M. Estimating bioavailability when clearance changes in time: the effect of model misspecification. 1995;58:599-600 (Letter reply)
—, Verotta D. Further notes on physiologic indirect response models. 1995;58:238-40 (Letter)
Shepherd AMM (*see* Jamieson et al). 1995;58:594
Shneyer L (*see* Brannan et al). 1995;58:269-78
Shukla UA (*see* Barbhaiya et al). 1995;58:390-8
Sigl G (*see* Jaehde et al). 1995;58:532-41
Sikich N (*see* Spahr-Schopfer et al). 1995;58:316-21
Simper D (*see* Peduzzi et al). 1995;58:675-83
Slattery JT (*see* Mitra et al). 1995;58:556-66
Slaughter RL (*see* Ducharme et al). 1995;58:617-24
Sneyd R (*see* Kishimoto et al). 1995;58:666-74
Soncrant TT (*see* Asthana et al). 1995;58:299-309
Sonnichsen DS, Ribeiro RC, Luo X, Mathew P, Relling MV. Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors. 1995;58:99-107
Sörgel F (*see* Jaehde et al). 1995;58:532-41
Spahr-Schopfer IA, Lerman J, Sikich N, Palmer J, Jorch U. Pharmacokinetics of intravenous ondansetron in healthy children undergoing ear, nose, and throat surgery. 1995;58:316-21
Spigset O, Carleborg L, Hedenmalm K, Dahlqvist R. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. 1995;58:399-403
Spreux-Varoquaux O (*see* Berlin et al). 1995;58:444-52
Sramek JJ (*see* Cutler et al). 1995;58:54-61
Stanski DR (*see* Fiset et al). 1995;58:567-82
Stein CM, Nelson R, Brown M, He H, Wood M, Wood AJJ. Dietary sodium intake modulates systemic but not forearm norepinephrine release. 1995;58:425-33
Stoltz M, Reynolds D, Elkins L, Salazar D, Weir S. Pharmacokinetics and pharmacodynamics of the monoamine oxidase B inhibitor mofegiline assessed during a phase I dose tolerance trial. 1995;58:342-53
Straka RJ, Hansen SR, Walker PF. Comparison of the prevalence of the poor metabolizer phenotype for CYP2D6 between 203 Hmong subjects and 280 white subjects residing in Minnesota. 1995;58:29-34
Strobel WM (*see* Peduzzi et al). 1995;58:675-83
Sundberg S (*see* Illi et al). 1995;58:221-7
Svensson JO (*see* Hartvig et al). 1995;58:165-73
Szylleyko OJ (*see* Cutler et al). 1995;58:54-61

T

Tateishi T (*see* Caraco et al). 1995;58:62-72
Temsamani J (*see* Zhang et al). 1995;58:44-53
Thummel KE (*see* Mitra et al). 1995;58:556-66
Tomlanovich SJ (*see* Gomez et al). 1995;58:15-9
Tomono Y (*see* Ishizaki et al). 1995;58:155-64
— (*see* Yasuda et al). 1995;58:143-54
Toyoki T (*see* Ishizaki et al). 1995;58:155-64
Transon C, Leemann T, Vogt N, Dayer P. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)-fluvastatin. 1995;58:412-7
Tse M (*see* Lai et al). 1995;58:264-8

U

Ufearo CS, Orisakwe OE. Restoration of normal sperm characteristics in hypoprolactinemic infertile men treated with metoclopramide and exogenous human prolactin. 1995;58:354-9
Unadkat JD (*see* Mitra et al). 1995;58:556-66

V

Valentino T (*see* Fong et al). 1995;58:192-7
Valtysson J (*see* Hartvig et al). 1995;58:165-73
van den Anker JN, Schoemaker RC, Hop WCJ, van der Heijden BJ, Weber A, Sauer PJJ, Neijens HJ, de Groot R. Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age. 1995;58:650-9
van der Heijden BJ (*see* van den Anker et al). 1995;58:650-9
Van de Velde V (*see* Ducharme et al). 1995;58:617-24
van Griensven JMT, Jusko WJ, Lemkes HHPJ, Kroon R, Verhorst CJ, Chiang ST, Cohen AF. Tolrestat pharmacokinetic and pharmacodynamic effects on red blood cell sorbitol levels in normal volunteers and in patients with insulin-dependent diabetes. 1995;58:631-40
Varhe A (*see* Hukkinen et al). 1995;58:127-31
Verhorst CJ (*see* van Griensven et al). 1995;58:631-40
Verotta D (*see* Fattinger and Verotta). 1995;58:595-9 (Letter)
— (*see* Sheiner and Verotta). 1995;58:238-40 (Letter)
Vogt N (*see* Transon et al). 1995;58:412-7
Vuorilehto L (*see* Huupponen et al). 1995;58:506-11

W

Wacher VJ (*see* Gomez et al). 1995;58:15-9
— (*see* Wu et al). 1995;58:492-7
Wagner O (*see* Blöchl-Daum et al). 1995;58:418-24
Walker PF (*see* Straka et al). 1995;58:29-34
Wang SL (*see* Lai et al). 1995;58:264-8
Warbasse LH (*see* Ducharme et al). 1995;58:617-24
Wardle TS (*see* Cutler et al). 1995;58:54-61
Weber A (*see* van den Anker et al). 1995;58:650-9
Weiner M (*see* Margarone et al). 1995;58:453-8
Weintraub M (*see* D'Agostino and Weintraub). 1995;58:605-16 (Commentary)
Weir S (*see* Stoltz et al). 1995;58:342-53
Welch RM, Brown A, Ravitch J, Dahl R. The in vitro degradation of cisatracurium, the *R, cis-R'*-isomer of atracurium, in human and rat plasma. 1995;58:132-42
Wellstein A (*see* Yasuda et al). 1995;58:210-20
Westerberg G (*see* Hartvig et al). 1995;58:165-73
White RH, Zhou H, Romano P, Mungall D. Changes in plasma warfarin levels and variations in steady-state prothrombin times. 1995;58:588-93
Wierda MKH (*see* Plaud et al). 1995;58:185-91
Wood AJJ (*see* Caraco et al). 1995;58:62-72

— (*see* Stein et al). 1995;58:425-33
Wood M (*see* Stein et al). 1995;58:425-33
Woodworth JR (*see* Howey et al). 1995;58:459-69
Woosley RL (*see* Hadidi et al). 1995;58:542-7
— (*see* Yasuda et al). 1995;58:210-20
Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, Wacher VJ. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. 1995;58:492-7

X

Xia H (*see* de Morais et al). 1995;58:404-11
Xiao ZS (*see* de Morais et al). 1995;58:404-11
Xie HG (*see* de Morais et al). 1995;58:404-11

Y

Yamato C (*see* Ishizaki et al). 1995;58:155-64
— (*see* Yasuda et al). 1995;58:143-54
Yan J (*see* Zhang et al). 1995;58:44-53
Yancey EP (*see* Hughes et al). 1995;58:434-43
Yasuda S, Horai Y, Tomono Y, Nakai H, Yamato C, Manabe K, Kobayashi K, Chiba K, Ishizaki T. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to *S*-mephenytoin 4′-hydroxylation status. 1995;58:143-54
— (*see* Ishizaki et al). 1995;58:155-64
Yasuda SU, Wellstein A, Likhari P, Barbey JT, Woosley RL. Chlorpheniramine plasma concentration and histamine H_1-receptor occupancy. 1995;58:210-20

Z

Zhang R, Yan J, Shahinian H, Amin G, Lu Z, Liu T, Saag MS, Jiang Z, Temsamani J, Martin RR, Schechter PJ, Agrawal S, Diasio RB. Pharmacokinetics of an anti–human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. 1995;58:44-53
— (*see* Lu et al). 1995;58:512-22
Zhi J, Rakhit A, Patel IH. Effects of dietary fat on drug absorption. 1995;58:487-91 (Commentary)
Zhou HH (*see* de Morais et al). 1995;58:404-11
Zhou H (*see* White et al). 1995;58:588-93
Ziegler WH (*see* Kupferschmidt et al). 1995;58:20-8
Zylber-Katz E, Caraco Y, Granit L, Levy M. Dipyrone metabolism in liver disease. 1995;58:198-209

Subject index

A

Acetylcholinesterases
Acetylcholinesterase inhibition by zifrosilone: pharmacokinetics and pharmacodynamics (Cutler et al). 1995;58:54-61

Adductor pollicis muscle
Pharmacokinetics and pharmacodynamics of rocuronium at the vocal cords and the adductor pollicis in humans (Plaud et al). 1995;58:185-91

Adefovir
Adefovir (USAN List No. 373). 1995;58:122

Administration, buccal
Buccal delivery of an α_2-adrenergic receptor antagonist, atipamezole, in humans (Huupponen et al). 1995;58:506-11

Adverse drug reactions
Comparison of the Bayesian approach and a simple algorithm for assessment of adverse drug events (Lanctôt and Naranjo). 1995;58:692-8

Age factors
Association of serum creatinine and age with headache caused by nitrates (Pahor et al). 1995;58:470-81
H_1- and H_2-histamine receptor–mediated vasodilation varies with aging in humans (Bedarida et al). 1995;58:73-80

Alendronate
Studies of the oral bioavailability of alendronate (Gertz et al). 1995;58:288-98

Algorithms
Comparison of the Bayesian approach and a simple algorithm for assessment of adverse drug events (Lanctôt and Naranjo). 1995;58:692-8

Alpha adrenergic receptors; *see* Receptors, adrenergic, alpha

Alzheimer's disease
Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease (Clipp and Moore). 1995;58:228-36
Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease (Asthana et al). 1995;58:299-309

American Society for Clinical Pharmacology and Therapeutics
Future meeting dates and sites of the ASCPT. 1995;58:119, 131
A message from the Finance Committee Chairperson. 1995;58:483
A message from the Government Affairs Committee Chairperson. 1995;58:118-9
A message from the President—Come to Walt Disney World, March 20-22, 1996. 1995;58:699
1996 ASCPT Clinical Pharmacology Curriculum Review Course. 1995;58:700
1996 ASCPT Workshop on Clinical Pharmacology in Primary Care Residency Education. 1995;58:700
Nominations for awards. 1995;58:360-1

Amlexanox
Amlexanox (USAN List No. 376). 1995;58:484

Analgesics
A comparison of crossover versus parallel-group design in the evaluation of analgesic efficacy after molar extraction (Margarone et al). 1995;58:453-8

Anastrozole
Anastrozole (USAN List No. 376). 1995;58:485

Angiotensin-converting enzyme inhibitors
Local angiotensin-converting enzyme inhibition blunts endothelin-1–induced increase in forearm vascular resistance (Abernethy et al). 1995;58:328-34

Angiotensin II
Pharmacokinetics of losartan, an angiotensin II receptor antagonist and its active metabolite EXP3174 in humans (Lo et al). 1995;58:641-9

Antiemetics
Pharmacokinetics of intravenous ondansetron in healthy children undergoing ear, nose, and throat surgery (Spahr-Schopfer et al). 1995;58:316-21

Antineoplastics
Availability of anticancer drugs in the United States, Europe, and Japan from 1960 through 1991 (Brown et al). 1995;58:243-56 (Commentary)

Antisense oligodeoxynucleotides; see Oligonucleotides, antisense

Arteflene
Arteflene (USAN List No. 376). 1995;58:484

Atipamezole
Buccal delivery of an α_2-adrenergic receptor antagonist, atipamezole, in humans (Huupponen et al). 1995;58:506-11

Atracurium
The in vitro degradation of cisatracurium, the *R, cis-R′*-isomer of atracurium, in human and rat plasma (Welch et al). 1995;58:132-42

Azithromycin
Azithromycin and terfenadine: lack of drug interaction (Harris et al). 1995;58:310-5

B

Balafilcon A
Balafilcon A (USAN List No. 377). 1995;58:604

Bayesian approach
Comparison of the Bayesian approach and a simple algorithm for assessment of adverse drug events (Lanctôt and Naranjo). 1995;58:692-8

Besipirdine hydrochloride
Besipirdine hydrochloride (USAN List No. 374). 1995;58:242

Biphosphonates
Studies of the oral bioavailability of alendronate (Gertz et al). 1995;58:288-98

Bivalirudin
Bivalirudin (USAN List No. 374). 1995;58:241

Blood pressure
Biphasic pressor responses to norepinephrine in humans (Sato et al). 1995;58:583-7

Books received
Books received. 1995;58:602

Bosentan
Bosentan (USAN List No. 375). 1995;58:362

Brain
Central nervous system effects of subdissociative doses of *(S)*-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers (Hartvig et al). 1995;58:165-73

Breast feeding
Active transport of cimetidine into human milk (Oo et al). 1995;58:548-55

Buccal administration; see Administration, buccal

C

Caffeine
Sympathomimetic effects of paraxanthine and caffeine in humans (Benowitz et al). 1995;58:684-91

Caregiver time use
Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease (Clipp and Moore). 1995;58:228-36

Catecholamines
Intravenous morphine and nalbuphine increase histamine and catecholamine release without accompanying hemodynamic changes (Doenicke et al). 1995;58:81-9

Ceftazidime
Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age (van den Anker et al). 1995;58:650-9

Central nervous system
Central nervous system effects of subdissociative doses of *(S)*-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers (Hartvig et al). 1995;58:165-73

Child
Length/serum creatinine ratio does not predict measured creatinine clearance in critically ill children (Fong et al). 1995;58:192-7
Norfloxacin interferes with cyclosporine disposition in pediatric patients undergoing renal transplantation (McLellan et al). 1995;58:322-7
Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors (Sonnichsen et al). 1995;58:99-107
Pharmacokinetics of intravenous ondansetron in healthy children undergoing ear, nose, and throat surgery (Spahr-Schopfer et al). 1995;58:316-21

China
Genetic analysis of the S-mephenytoin polymorphism in a Chinese population (de Morais et al). 1995;58:404-11
Propranolol disposition in Chinese subjects of different *CYP2D6* genotypes (Lai et al). 1995;58:264-8

Chloroguanide
Comparison of chloroguanide and mephenytoin for the in vivo assessment of genetically determined CYP2C19 activity in humans (Partovian et al). 1995;58:257-63

Chlorpheniramine
Chlorpheniramine plasma concentration and histamine H_1-receptor occupancy (Yasuda et al). 1995;58:210-20

Cidofovir
Cidofovir (USAN List No. 373). 1995;58:122

Cigarette smoking; see Smoking

Cimetidine
Active transport of cimetidine into human milk (Oo et al). 1995;58:548-55

Ciprofloxacin
Effect of probenecid on the distribution and elimination of ciprofloxacin in humans (Jaehde et al). 1995;58:532-41

Cisatracurium
The in vitro degradation of cisatracurium, the *R, cis-R´*-isomer of atracurium, in human and rat plasma (Welch et al). 1995;58:132-42

Cisplatin
Effects of cisplatin on urinary thromboxane B_2 excretion (Blöchl-Daum et al). 1995;58:418-24

Clinical trials
Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease (Clipp and Moore). 1995;58:228-36
Success rates for new drugs entering clinical testing in the United States (DiMasi). 1995;58:1-14 (Commentary)

Commentaries
Commentaries. 1995;58:1-14, 123-6, 243-56, 487-91, 605-16

Compliance
Miscompliance by proxy (Jamieson et al). 1995;58:594

Congestive heart failure; see Heart failure, congestive

Conscious sedation
Topographic electroencephalogram of propofol-induced conscious sedation (Kishimoto et al). 1995;58:666-74

Contraceptives, oral
Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive (Saano et al). 1995;58:523-31

Correction
Population pharmacokinetics of vancomycin in neonates (Seay et al) (1994;56:169-75). 1995;58:142

Correspondence; see Letters

Creatinine
Association of serum creatinine and age with headache caused by nitrates (Pahor et al). 1995;58:470-81
Length/serum creatinine ratio does not predict measured creatinine clearance in critically ill children (Fong et al). 1995;58:192-7

Cyclic guanosine monophosphate; see Guanosine cyclic monophosphate

Cyclosporine
Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine (Wu et al). 1995;58:492-7
The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine (Gomez et al). 1995;58:15-9
Norfloxacin interferes with cyclosporine disposition in pediatric patients undergoing renal transplantation (McLellan et al). 1995;58:322-7

Cytochrome P450
Comparative effects of omeprazole on xenobiotic metabolizing enzymes in the rat and human (Kashfi et al). 1995;58:625-30
Comparison of chloroguanide and mephenytoin for the in vivo assessment of genetically determined CYP2C19 activity in humans (Partovian et al). 1995;58:257-63
Comparison of the prevalence of the poor metabolizer phenotype for CYP2D6 between 203 Hmong subjects and 280 white subjects residing in Minnesota (Straka et al). 1995;58:29-34
Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans (Fromm et al). 1995;58:374-82
In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)-fluvastatin (Transon et al). 1995;58:412-7
Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo (Mitra et al). 1995;58:556-66
Propranolol disposition in Chinese subjects of different *CYP2D6* genotypes (Lai et al). 1995;58:264-8
Urinary excretion of 6-hydroxychlorzoxazone as an index of CYP2E1 activity (Dreisbach et al). 1995;58:498-505

D

Dacliximab
Dacliximab (USAN List No. 375). 1995;58:363-4

Dapsone
Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo (Mitra et al). 1995;58:556-66

Delequamine hydrochloride
Delequamine hydrochloride (USAN List No. 374). 1995;58:242

Desirudin
Desirudin (USAN List No. 374). 1995;58:241

Diabetes
Tolrestat pharmacokinetic and pharmacodynamic effects on red blood cell sorbitol levels in normal volunteers and in patients with insulin-dependent diabetes (van Griensven et al). 1995;58:631-40

Diazepam
Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of *S*-mephenytoin 4′-hydroxylation (Ishizaki et al). 1995;58:155-64
Interethnic difference in omeprazole's inhibition of diazepam metabolism (Caraco et al). 1995;58:62-72
Simultaneous modeling of the pharmacokinetics and pharmacodynamics of midazolam and diazepam (Mould et al). 1995;58:35-43

Diet
Dietary sodium intake modulates systemic but not forearm norepinephrine release (Stein et al). 1995;58:425-33
Effects of dietary fat on drug absorption (Zhi et al). 1995;58:487-91 (Commentary)

Dihydrocodeine
Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans (Fromm et al). 1995;58:374-82

Dipyrone
Dipyrone metabolism in liver disease (Zylber-Katz et al). 1995;58:198-209

Drug absorption
Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine (Wu et al). 1995;58:492-7
Effects of dietary fat on drug absorption (Zhi et al). 1995;58:487-91 (Commentary)

Drug availability
Availability of anticancer drugs in the United States, Europe, and Japan from 1960 through 1991 (Brown et al). 1995;58:243-56 (Commentary)

Drug development
Clinical pharmacology and drug safety: lessons from hirudin (Conrad). 1995;58:123-6 (Commentary)
Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective (Bakke et al). 1995;58:108-17
Success rates for new drugs entering clinical testing in the United States (DiMasi). 1995;58:1-14 (Commentary)

Drug interactions
Azithromycin and terfenadine: lack of drug interaction (Harris et al). 1995;58:310-5
Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of *S*-mephenytoin 4′-hydroxylation (Ishizaki et al). 1995;58:155-64
The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine (Illi et al). 1995;58:221-7
Effect of probenecid on the distribution and elimination of ciprofloxacin in humans (Jaehde et al). 1995;58:532-41
Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive (Saano et al). 1995;58:523-31
Effects of felbamate on the pharmacokinetics of phenobarbital (Reidenberg et al). 1995;58:279-87
Effects of felbamate on the pharmacokinetics of the monohydroxy and dihydroxy metabolites of oxcarbazepine (Hulsman et al). 1995;58:383-9
The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine (Gomez et al). 1995;58:15-9
Interethnic difference in omeprazole's inhibition of diazepam metabolism (Caraco et al). 1995;58:62-72
Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin (Ducharme et al). 1995;58:617-24
Norfloxacin interferes with cyclosporine disposition in pediatric patients undergoing renal transplantation (McLellan et al). 1995;58:322-7
Sympathomimetic effects of paraxanthine and caffeine in humans (Benowitz et al). 1995;58:684-91

Drug tolerance
Pharmacokinetics and pharmacodynamics of the monoamine oxidase B inhibitor mofegiline assessed during a phase I dose tolerance trial (Stoltz et al). 1995;58:342-53

E

E3810
Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of *S*-mephenytoin 4′-hydroxylation (Ishizaki et al). 1995;58:155-64
Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to *S*-mephenytoin 4′-hydroxylation status (Yasuda et al). 1995;58:143-54

Ecadotril
Ecadotril (USAN List No. 376). 1995;58:485

Electrocardiography
Loratadine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations (Brannan et al). 1995;58:269-78

Electroencephalography
Pharmacodynamic modeling of the electroencephalographic effects of flumazenil in healthy volunteers sedated with midazolam (Fiset et al). 1995;58:567-82
Topographic electroencephalogram of propofol-induced conscious sedation (Kishimoto et al). 1995;58:666-74

Embutramide
Embutramide (USAN List No. 376). 1995;58:486

Enantiomers
Verapamil stereoisomerism: enantiomeric ratios in plasma dependent on peak concentrations, oral input rate, or both (Karim and Piergies). 1995;58:174-84

Endothelins
Local angiotensin-converting enzyme inhibition blunts endothelin-1–induced increase in forearm vascular resistance (Abernethy et al). 1995;58:328-34

Enoxaparin sodium
Enoxaparin sodium (USAN List No. 376). 1995;58:485

Entacapone
The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine (Illi et al). 1995;58:221-7

Enzymes
Comparative effects of omeprazole on xenobiotic metabolizing enzymes in the rat and human (Kashfi et al). 1995;58:625-30

Epinephrine
The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine (Illi et al). 1995;58:221-7

Eprinomectin
Eprinomectin (USAN List No. 376). 1995;58:486

Erythrocytes
Tolrestat pharmacokinetic and pharmacodynamic effects on red blood cell sorbitol levels in normal volunteers and in patients with insulin-dependent diabetes (van Griensven et al). 1995;58:631-40

Erythromycin
Loratadine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations (Brannan et al). 1995;58:269-78

Erythromycin salnacedin
Erythromycin salnacedin (USAN List No. 375). 1995;58:362

Ethnic factors
Comparison of the prevalence of the poor metabolizer phenotype for CYP2D6 between 203 Hmong subjects and 280 white subjects residing in Minnesota (Straka et al). 1995;58:29-34
Interethnic difference in omeprazole's inhibition of diazepam metabolism (Caraco et al). 1995;58:62-72

Etoposide
Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors (Sonnichsen et al). 1995;58:99-107

Europe
Availability of anticancer drugs in the United States, Europe, and Japan from 1960 through 1991 (Brown et al). 1995;58:243-56 (Commentary)

Exercise
Hemoglobin-based oxygen carrier preserves submaximal exercise capacity in humans (Hughes et al). 1995;58:434-43

EXP3174
Pharmacokinetics of losartan, an angiotensin II receptor antagonist and its active metabolite EXP3174 in humans (Lo et al). 1995;58:641-9

F

Fat
Effects of dietary fat on drug absorption (Zhi et al). 1995;58:487-91 (Commentary)

Felbamate
Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive (Saano et al). 1995;58:523-31
Effects of felbamate on the pharmacokinetics of phenobarbital (Reidenberg et al). 1995;58:279-87
Effects of felbamate on the pharmacokinetics of the monohydroxy and dihydroxy metabolites of oxcarbazepine (Hulsman et al). 1995;58:383-9

Flumazenil
Pharmacodynamic modeling of the electroencephalographic effects of flumazenil in healthy volunteers sedated with midazolam (Fiset et al). 1995;58:567-82

Fluorouracil
Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy (Lu et al). 1995;58:512-22

Fluvastatin
In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)-fluvastatin (Transon et al). 1995;58:412-7

Fluvoxamine
Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans (Spigset et al). 1995;58:399-403

Fluvoxamine maleate
Fluvoxamine maleate (USAN List No. 376). 1995;58:484

Food and Drug Administration
Success rates for new drugs entering clinical testing in the United States (DiMasi). 1995;58:1-14 (Commentary)

Food-drug interactions
The fate of naringin in humans: A key to grapefruit juice–drug interactions? (Fuhr and Kummert). 1995;58:365-73
Interaction between grapefruit juice and midazolam in humans (Kupferschmidt et al). 1995;58:20-8
Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice (Hukkinen et al). 1995;58:127-31

Fosinopril
Fosinopril: pharmacokinetics and pharmacodynamics in congestive heart failure (Kostis et al). 1995;58:660-5

G

Galdansetron hydrochloride
Galdansetron hydrochloride (USAN List No. 377). 1995;58:604

Genetics
Genetic analysis of the *S*-mephenytoin polymorphism in a Chinese population (de Morais et al). 1995;58:404-11
S-Mephenytoin hydroxylation phenotypes in a Jordanian population (Hadidi et al). 1995;58:542-7

Gestational age
Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age (van den Anker et al). 1995;58:650-9

Glomerular filtration rate
Length/serum creatinine ratio does not predict measured creatinine clearance in critically ill children (Fong et al). 1995;58:192-7

Glucocorticoids
Glucocorticoid-induced sympathoinhibition in humans (Golczynska et al). 1995;58:90-8

Glucose
[Lys(B28), Pro(B29)]–human insulin: effect of injection time on postprandial glycemia (Howey et al). 1995;58:459-69

Glycemia
[Lys(B28), Pro(B29)]–human insulin: effect of injection time on postprandial glycemia (Howey et al). 1995;58:459-69

Grapefruit juice
The fate of naringin in humans: A key to grapefruit juice–drug interactions? (Fuhr and Kummert). 1995;58:365-73
Interaction between grapefruit juice and midazolam in humans (Kupferschmidt et al). 1995;58:20-8
Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice (Hukkinen et al). 1995;58:127-31

Guanosine cyclic monophosphate
Neuropeptide Y in human hand veins: pharmacologic characterization and interaction with cyclic guanosine monophosphate–dependent venodilators in vivo (Peduzzi et al). 1995;58:675-83

Guest reviewers
Guest reviewers. 1995;58:482

H

Hand
Neuropeptide Y in human hand veins: pharmacologic characterization and interaction with cyclic guanosine monophosphate–dependent venodilators in vivo (Peduzzi et al). 1995;58:675-83

Headache
Association of serum creatinine and age with headache caused by nitrates (Pahor et al). 1995;58:470-81

Heart failure, congestive
Fosinopril: pharmacokinetics and pharmacodynamics in congestive heart failure (Kostis et al). 1995;58:660-5

Heart rate
Biphasic pressor responses to norepinephrine in humans (Sato et al). 1995;58:583-7

Hemodynamics
The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine (Illi et al). 1995;58:221-7

Intravenous morphine and nalbuphine increase histamine and catecholamine release without accompanying hemodynamic changes (Doenicke et al). 1995;58:81-9

Hemoglobin
Hemoglobin-based oxygen carrier preserves submaximal exercise capacity in humans (Hughes et al). 1995;58:434-43

Hepatic cirrhosis; see Liver cirrhosis

Hirudin
Clinical pharmacology and drug safety: lessons from hirudin (Conrad). 1995;58:123-6 (Commentary)

Histamine
Chlorpheniramine plasma concentration and histamine H_1-receptor occupancy (Yasuda et al). 1995;58:210-20
H_1- and H_2-histamine receptor–mediated vasodilation varies with aging in humans (Bedarida et al). 1995;58:73-80
Intravenous morphine and nalbuphine increase histamine and catecholamine release without accompanying hemodynamic changes (Doenicke et al). 1995;58:81-9

HIV
Pharmacokinetics of an anti–human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects (Zhang et al). 1995;58:44-53

Hmong
Comparison of the prevalence of the poor metabolizer phenotype for CYP2D6 between 203 Hmong subjects and 280 white subjects residing in Minnesota (Straka et al). 1995;58:29-34

Human milk; see Milk, human

Hydroxychlorzosazone
Urinary excretion of 6-hydroxychlorzoxazone as an index of CYP2E1 activity (Dreisbach et al). 1995;58:498-505

Hydroxyitraconazole
Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin (Ducharme et al). 1995;58:617-24

Hypoprolactinemia
Restoration of normal sperm characteristics in hypoprolactinemic infertile men treated with metoclopramide and exogenous human prolactin (Ufearo and Orisakwe). 1995;58:354-9

I

Infant, premature
Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age (van den Anker et al). 1995;58:650-9

Infertility
Restoration of normal sperm characteristics in hypoprolactinemic infertile men treated with metoclopramide and exogenous human prolactin (Ufearo and Orisakwe). 1995;58:354-9

Insulin
[Lys(B28), Pro(B29)]–human insulin: effect of injection time on postprandial glycemia (Howey et al). 1995;58:459-69
Tolrestat pharmacokinetic and pharmacodynamic effects on red blood cell sorbitol levels in normal volunteers and in patients with insulin-dependent diabetes (van Griensven et al). 1995;58:631-40

Intestines
Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine (Wu et al). 1995;58:492-7
The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine (Gomez et al). 1995;58:15-9

Investigational new drugs
Success rates for new drugs entering clinical testing in the United States (DiMasi). 1995;58:1-14 (Commentary)

Irinotecan hydrochloride
Irinotecan hydrochloride (USAN List No. 377). 1995;58:603

Isoproterenol
The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine (Illi et al). 1995;58:221-7

Itraconazole
Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin (Ducharme et al). 1995;58:617-24

J

Japan
Availability of anticancer drugs in the United States, Europe, and Japan from 1960 through 1991 (Brown et al). 1995;58:243-56 (Commentary)

Jordan
S-Mephenytoin hydroxylation phenotypes in a Jordanian population (Hadidi et al). 1995;58:542-7

K

Ketamine
Central nervous system effects of subdissociative doses of *(S)*-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers (Hartvig et al). 1995;58:165-73

Ketoconazole
The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine (Gomez et al). 1995;58:15-9

Kidney
Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age (van den Anker et al). 1995;58:650-9

Kidney transplantation
Norfloxacin interferes with cyclosporine disposition in pediatric patients undergoing renal transplantation (McLellan et al). 1995;58:322-7

L

Letters
Buspirone miosis (Berlin) (Letter); (Fanciullacci and Geppetti) (Reply). 1995;58:600-1
Estimating bioavailability when clearance changes in time: the effect of model misspecification (Fattinger and Verotta) (Letter); (Sheiner and Karlsson) (Reply). 1995;58:595-600
Further notes on physiologic indirect response models (Sheiner and Verotta). 1995;58:238-40
The role of oral dihydroergotamine in the management of vascular disorders (Rumboldt et al). 1995;58:237-8

Liver
Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine (Wu et al). 1995;58:492-7
Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy (Lu et al). 1995;58:512-22

Liver cirrhosis
Single- and multiple-dose pharmacokinetics of nefazodone in patients with hepatic cirrhosis (Barbhaiya et al). 1995;58:390-8

Liver disease
Dipyrone metabolism in liver disease (Zylber-Katz et al). 1995;58:198-209

Loratadine
Loratadine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations (Brannan et al). 1995;58:269-78

Losartan
Pharmacokinetics of losartan, an angiotensin II receptor antagonist and its active metabolite EXP3174 in humans (Lo et al). 1995;58:641-9

M

Mephenytoin
Comparison of chloroguanide and mephenytoin for the in vivo assessment of genetically determined CYP2C19 activity in humans (Partovian et al). 1995;58:257-63
Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of *S*-mephenytoin 4´-hydroxylation (Ishizaki et al). 1995;58:155-64
Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to *S*-mephenytoin 4´-hydroxylation status (Yasuda et al). 1995;58:143-54
Genetic analysis of the *S*-mephenytoin polymorphism in a Chinese population (de Morais et al). 1995;58:404-11
S-Mephenytoin hydroxylation phenotypes in a Jordanian population (Hadidi et al). 1995;58:542-7

Meta-analysis
Meta-analysis: a method for synthesizing research (D'Agostino and Weintraub). 1995;58:605-16 (Commentary)

Metoclopramide
Restoration of normal sperm characteristics in hypoprolactinemic infertile men treated with metoclopramide and exogenous human prolactin (Ufearo and Orisakwe). 1995;58:354-9

Mibefradil dihydrochloride
Mibefradil dihydrochloride (USAN List No. 373). 1995;58:121

Midazolam
Pharmacodynamic modeling of the electroencephalographic effects of flumazenil in healthy volunteers sedated with midazolam (Fiset et al). 1995;58:567-82
Simultaneous modeling of the pharmacokinetics and pharmacodynamics of midazolam and diazepam (Mould et al). 1995;58:35-43

Milk, human
Active transport of cimetidine into human milk (Oo et al). 1995;58:548-55

Moclobemide
A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers (Berlin et al). 1995;58:444-52

Mofegiline
Pharmacokinetics and pharmacodynamics of the monoamine oxidase B inhibitor mofegiline assessed during a phase I dose tolerance trial (Stoltz et al). 1995;58:342-53

Molar extraction; see Tooth extraction

Monatepil maleate
Monatepil maleate (USAN List No. 378). 1995;58:701

Monoamine oxidase inhibitors
Pharmacokinetics and pharmacodynamics of the monoamine oxidase B inhibitor mofegiline assessed during a phase I dose tolerance trial (Stoltz et al). 1995;58:342-53
A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers (Berlin et al). 1995;58:444-52

Morphine
Intravenous morphine and nalbuphine increase histamine and catecholamine release without accompanying hemodynamic changes (Doenicke et al). 1995;58:81-9

N

Nabumetone
Effects of nabumetone on prostanoid biosynthesis in humans (Cipollone et al). 1995;58:335-41

Nalbuphine
Intravenous morphine and nalbuphine increase histamine and catecholamine release without accompanying hemodynamic changes (Doenicke et al). 1995;58:81-9

Naringin
The fate of naringin in humans: A key to grapefruit juice–drug interactions? (Fuhr and Kummert). 1995;58:365-73

Nausea
Pharmacokinetics of intravenous ondansetron in healthy children undergoing ear, nose, and throat surgery (Spahr-Schopfer et al). 1995;58:316-21

Nefazodone
Single- and multiple-dose pharmacokinetics of nefazodone in patients with hepatic cirrhosis (Barbhaiya et al). 1995;58:390-8

Neoplasms
Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors (Sonnichsen et al). 1995;58:99-107

Neuropeptides
Neuropeptide Y in human hand veins: pharmacologic characterization and interaction with cyclic guanosine monophosphate–dependent venodilators in vivo (Peduzzi et al). 1995;58:675-83

New biological entities
Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective (Bakke et al). 1995;58:108-17

New chemical entities
Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective (Bakke et al). 1995;58:108-17
Success rates for new drugs entering clinical testing in the United States (DiMasi). 1995;58:1-14 (Commentary)

Nitrates
Association of serum creatinine and age with headache caused by nitrates (Pahor et al). 1995;58:470-81

Norepinephrine
Biphasic pressor responses to norepinephrine in humans (Sato et al). 1995;58:583-7
Dietary sodium intake modulates systemic but not forearm norepinephrine release (Stein et al). 1995;58:425-33
Glucocorticoid-induced sympathoinhibition in humans (Golczynska et al). 1995;58:90-8

Norfloxacin
Norfloxacin interferes with cyclosporine disposition in pediatric patients undergoing renal transplantation (McLellan et al). 1995;58:322-7

O

Oligonucleotides, antisense
Pharmacokinetics of an anti–human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects (Zhang et al). 1995;58:44-53

Omeprazole
Comparative effects of omeprazole on xenobiotic metabolizing enzymes in the rat and human (Kashfi et al). 1995;58:625-30
Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of *S*-mephenytoin 4´-hydroxylation (Ishizaki et al). 1995;58:155-64

Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to *S*-mephenytoin 4´-hydroxylation status (Yasuda et al). 1995;58:143-54
Interethnic difference in omeprazole's inhibition of diazepam metabolism (Caraco et al). 1995;58:62-72

Ondansetron
Pharmacokinetics of intravenous ondansetron in healthy children undergoing ear, nose, and throat surgery (Spahr-Schopfer et al). 1995;58:316-21

Ontazolast
Ontazolast (USAN List No. 373). 1995;58:121

Opioids
Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans (Fromm et al). 1995;58:374-82

Oral contraceptives; see Contraceptives, oral

Oxcarbazepine
Effects of felbamate on the pharmacokinetics of the monohydroxy and dihydroxy metabolites of oxcarbazepine (Hulsman et al). 1995;58:383-9

Oxygen
Hemoglobin-based oxygen carrier preserves submaximal exercise capacity in humans (Hughes et al). 1995;58:434-43

P

Paraxanthine
Sympathomimetic effects of paraxanthine and caffeine in humans (Benowitz et al). 1995;58:684-91

Patient compliance
Miscompliance by proxy (Jamieson et al). 1995;58:594

Pediatrics; see Child

Pegorgotein
Pegorgotein (USAN List No. 374). 1995;58:242

Phenobarbital
Effects of felbamate on the pharmacokinetics of phenobarbital (Reidenberg et al). 1995;58:279-87

Phenytoin
Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin (Ducharme et al). 1995;58:617-24

Phosphorothioate
Pharmacokinetics of an anti–human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects (Zhang et al). 1995;58:44-53

Physostigmine
Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease (Asthana et al). 1995;58:299-309

Plasma
Central nervous system effects of subdissociative doses of *(S)*-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers (Hartvig et al). 1995;58:165-73
Changes in plasma warfarin levels and variations in steady-state prothrombin times (White et al). 1995;58:588-93
Chlorpheniramine plasma concentration and histamine H_1-receptor occupancy (Yasuda et al). 1995;58:210-20
Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice (Hukkinen et al). 1995;58:127-31
Verapamil stereoisomerism: enantiomeric ratios in plasma dependent on peak concentrations, oral input rate, or both (Karim and Piergies). 1995;58:174-84
The in vitro degradation of cisatracurium, the *R, cis-R´*-isomer of atracurium, in human and rat plasma (Welch et al). 1995;58:132-42

Population studies
Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy (Lu et al). 1995;58:512-22

Positron emission tomography; see Tomography, emission-computed

Preterm infant; see Infant, premature

Probenecid
Effect of probenecid on the distribution and elimination of ciprofloxacin in humans (Jaehde et al). 1995;58:532-41

Prolactin
Restoration of normal sperm characteristics in hypoprolactinemic infertile men treated with metoclopramide and exogenous human prolactin (Ufearo and Orisakwe). 1995;58:354-9

Propofol
Topographic electroencephalogram of propofol-induced conscious sedation (Kishimoto et al). 1995;58:666-74

Propranolol
Propranolol disposition in Chinese subjects of different *CYP2D6* genotypes (Lai et al). 1995;58:264-8

Prostanoids
Effects of nabumetone on prostanoid biosynthesis in humans (Cipollone et al). 1995;58:335-41

Prothrombin time
Changes in plasma warfarin levels and variations in steady-state prothrombin times (White et al). 1995;58:588-93

Proton pump inhibitor
Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of *S*-mephenytoin 4´-hydroxylation (Ishizaki et al). 1995;58:155-64
Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to *S*-mephenytoin 4´-hydroxylation status (Yasuda et al). 1995;58:143-54

R

Receptors, adrenergic, alpha
Buccal delivery of an α_2-adrenergic receptor antagonist, atipamezole, in humans (Huupponen et al). 1995;58:506-11

Red blood cells; see Erythrocytes

Renal transplantation; see Kidney transplantation

Research
Meta-analysis: a method for synthesizing research (D'Agostino and Weintraub). 1995;58:605-16 (Commentary)

Riluzole
Riluzole (USAN List No. 377). 1995;58:604

Rocuronium
Pharmacokinetics and pharmacodynamics of rocuronium at the vocal cords and the adductor pollicis in humans (Plaud et al). 1995;58:185-91

S

Safety
Clinical pharmacology and drug safety: lessons from hirudin (Conrad). 1995;58:123-6 (Commentary)
Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective (Bakke et al). 1995;58:108-17

Salnacedin
Salnacedin (USAN List No. 378). 1995;58:702

Saprisartan potassium
Saprisartan potassium (USAN List No. 378). 1995;58:702

Smoking
Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans (Spigset et al). 1995;58:399-403
A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers (Berlin et al). 1995;58:444-52

Sodium
Dietary sodium intake modulates systemic but not forearm norepinephrine release (Stein et al). 1995;58:425-33

Sodium phenylbutyrate
Sodium phenylbutyrate (USAN List No. 378). 1995;58:701

Sorbitol
Tolrestat pharmacokinetic and pharmacodynamic effects on red blood cell sorbitol levels in normal volunteers and in patients with insulin-dependent diabetes (van Griensven et al). 1995;58:631-40

Spain
Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective (Bakke et al). 1995;58:108-17

Sperm
Restoration of normal sperm characteristics in hypoprolactinemic infertile men treated with metoclopramide and exogenous human prolactin (Ufearo and Orisakwe). 1995;58:354-9

Sympathetic nervous system
Glucocorticoid-induced sympathoinhibition in humans (Golczynska et al). 1995;58:90-8

T

Tasosartan
Tasosartan (USAN List No. 378). 1995;58:702

Tazarotene
Tazarotene (USAN List No. 373). 1995;58:120

Tazofelone
Tazofelone (USAN List No. 373). 1995;58:121

Temoporfin
Temoporfin (USAN List No. 377). 1995;58:6[illegible]3

Terfenadine
Azithromycin and terfenadine: lack of drug interaction (Harris et al). 1995;58:310-5

Thromboxanes
Effects of cisplatin on urinary thromboxane B_2 excretion (Blöchl-Daum et al). 1995;58:418-24

Tirofiban hydrochloride
Tirofiban hydrochloride (USAN List No. 373). 1995;58:122

Tolrestat
Tolrestat pharmacokinetic and pharmacodynamic effects on red blood cell sorbitol levels in normal volunteers and in patients with insulin-dependent diabetes (van Griensven et al). 1995;58:631-40

Tomography, emission-computed
Central nervous system effects of subdissociative doses of *(S)*-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers (Hartvig et al). 1995;58:165-73

Tooth extraction
A comparison of crossover versus parallel-group design in the evaluation of analgesic efficacy after molar extraction (Margarone et al). 1995;58:453-8

Topographic electroencephalography; *see* Electroencephalography

Triazolam
Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice (Hukkinen et al). 1995;58:127-31

Troglitazone
Troglitazone (USAN List No. 378). 1995;58:702

Tumors; see Neoplasms

U

United Kingdom
Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective (Bakke et al). 1995;58:108-17

United States Adopted Names Council
USAN Council. 1995;58:120-2, 241-2, 362-4, 484-6, 603-4, 701-2

Urine
Effects of cisplatin on urinary thromboxane B_2 excretion (Blöchl-Daum et al). 1995;58:418-24
Urinary excretion of 6-hydroxychlorzoxazone as an index of CYP2E1 activity (Dreisbach et al). 1995;58:498-505

V

Vascular resistance
Local angiotensin-converting enzyme inhibition blunts endothelin-1–induced increase in forearm vascular resistance (Abernethy et al). 1995;58:328-34

Vasodilation
H_1- and H_2-histamine receptor–mediated vasodilation varies with aging in humans (Bedarida et al). 1995;58:73-80
Neuropeptide Y in human hand veins: pharmacologic characterization and interaction with cyclic guanosine monophosphate–dependent venodilators in vivo (Peduzzi et al). 1995;58:675-83

Veins
Neuropeptide Y in human hand veins: pharmacologic characterization and interaction with cyclic guanosine monophosphate–dependent venodilators in vivo (Peduzzi et al). 1995;58:675-83

Verapamil
Verapamil stereoisomerism: enantiomeric ratios in plasma dependent on peak concentrations, oral input rate, or both (Karim and Piergies). 1995;58:174-84

Vocal cords
Pharmacokinetics and pharmacodynamics of rocuronium at the vocal cords and the adductor pollicis in humans (Plaud et al). 1995;58:185-91

W

Warfarin
Changes in plasma warfarin levels and variations in steady-state prothrombin times (White et al). 1995;58:588-93

X

Xanomeline tartrate
Xanomeline tartrate (USAN List No. 373). 1995;58:120

Z

Zafirlukast
Zafirlukast (USAN List No. 378). 1995;58:701

Zaleplon
Zaleplon (USAN List No. 373). 1995;58:120

Zifrosilone
Acetylcholinesterase inhibition by zifrosilone: pharmacokinetics and pharmacodynamics (Cutler et al). 1995;58:54-61